July 8 — AstraZeneca and Ionis launched eplontersen sodium injection (brand name
Wanovive) in China. The drug was approved in China in December 2025 for
treatment of adults with hereditary transthyretin-mediated amyloid
polyneuropathy (ATTRv-PN).
2026-07-09
July 8 — AstraZeneca and Ionis launched eplontersen sodium injection (brand name
Wanovive) in China. The drug was approved in China in December 2025 for
treatment of adults with hereditary transthyretin-mediated amyloid
polyneuropathy (ATTRv-PN).